You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208838

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 208838 describes NYSTATIN, which is a drug marketed by Actavis Mid Atlantic, Cosette, Crown Labs Inc, Fougera Pharms, Perrigo New York, Taro, Torrent, Vintage, Cadila, Lyne, Paddock Llc, Epic Pharma Llc, Lupin, Mayne Pharma Inc, Nesher Pharms, Upsher Smith Labs, Xgen Pharms, Alpharma Us Pharms, Fougera Pharms Inc, G And W Labs Inc, Hi Tech Pharma, Lannett Co Inc, Morton Grove, Pharm Assoc, Pharmaderm, Pharmafair, Socorro, Teva, Vistapharm, Wockhardt Bio Ag, Heritage Pharms Inc, Quantum Pharmics, Sandoz, Sun Pharm Industries, Watson Labs, Fougera, Odyssey Pharms, Amneal Pharms Llc, Dr Reddys, Glenmark Pharms Ltd, Lupin Ltd, Perrigo Uk Finco, Akorn, Rising, Strides Pharma, Teligent Pharma Inc, and Vitruvias Therap, and is included in eighty-three NDAs. It is available from thirty-seven suppliers. Additional details are available on the NYSTATIN profile page.

The generic ingredient in NYSTATIN is nystatin; triamcinolone acetonide. There are eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the nystatin; triamcinolone acetonide profile page.
Summary for 208838
Formulation / Manufacturing:see details
Pharmacology for NDA: 208838
Medical Subject Heading (MeSH) Categories for 208838
Suppliers and Packaging for NDA: 208838
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NYSTATIN nystatin POWDER;TOPICAL 208838 ANDA Leading Pharma, LLC 69315-306 69315-306-15 15 g in 1 BOTTLE, PLASTIC (69315-306-15)
NYSTATIN nystatin POWDER;TOPICAL 208838 ANDA Leading Pharma, LLC 69315-306 69315-306-30 30 g in 1 BOTTLE, PLASTIC (69315-306-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;TOPICALStrength100,000 UNITS/GM
Approval Date:May 30, 2017TE:ATRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.